Mark began his legal career as a law clerk for The Hon. James K. Logan of the U.S. Court of Appeals, Tenth Judicial Circuit. Since then, his practice has focused on nationwide complex litigation, including the defense of pharmaceutical and medical device manufacturers. Such litigation has involved numerous cases in state and federal trial and appellate courts throughout the United States.

Mark has spoken on numerous occasions regarding various litigation topics, including at several Drug Information Association meetings and at the Defense Research Institute's Pharmaceutical and Medical Device Annual Meeting. He has assisted in program scheduling for the Drug Information Association's Annual Meeting since 1995. Before pursuing a legal career, Mark worked as a process engineer for AT&T in its semiconductor manufacturing division.

Complex Litigation – Since 1991, Mark has represented numerous companies in a variety of complex litigations. These litigations, among other things, have involved product liability claims, insurance coverage disputes, advertising claims and securities.

Mark's representative clients include Astellas Pharma US, Inc., for which he serves as national counsel in cases involving the topical medication Protopic®, and Upsher-Smith Laboratories, Inc., for which he serves as national counsel for all product cases. Mark also currently represents Pfizer in cases involving Zoloft®, Lipitor® and HRT, Boston Scientific in cases involving pelvic mesh, and Hoffmann-La Roche in cases involving Accutane®. Other representations have included Eli Lilly and Company on a nationwide basis in cases involving Prozac® and diethylstilbestrol, American Home Products Corporation in cases involving Cordarone®, Wyeth in cases involving diet drugs, Sanofi Inc. in litigation involving Marcaine®, Organon in cases involving Raplon® and Zemuron®, Akzo Nobel in cases involving coatings, the Dalkon Shield Claimants Trust in litigation involving the Dalkon Shield IUD and G.D. Searle & Company in cases involving the Cu-7 IUD, and American Cyanamid Company in cases involving claims of yield loss and exposure to antibiotics.

Publications and Presentations

What's Left After Mensing, DRI Drug and Medical Device Committee Webcast, 2013.

Potential Civil and Criminal Liability Arising from Clinical Trials, DRI Pharmaceutical and Medical Device Annual Meeting, 2009.

Clinical Trials on Trial: Potential Legal Liability from Clinical Research, Achieving Excellence in Clinical Research, 2009.

Clinical Trial Litigation: Potential Legal Liability Arising from Clinical Trials, HARP Annual Meeting, 2008.

Direct and Cross Examination of a Hypothetical Principle Investigator, DIA Annual Meeting, 1997.

Mock Trial of a Clinical Investigator, ARC, 1997.

Demonstration of a Pharmaceutical Products Liability Trial, DIA Legal Liability Seminar, 1997 and DIA Annual Meetings 1995, 1996, 1998-2013.

Hegarty, et al., Reliability not Quantity the Key Under Daubert, The Journal of the Academy of Experts, Vol. 5, No. 2, Summer 2000.